September 30, 2016: Just a day after Hanmi Pharma announced a deal with Genentech, Boehringer Ingelheim terminated a license deal because of patient deaths.
September 30, 2016: After a strategic review of its operations and pipeline, Waltham, MA-based ImmunoGen announced yesterday that it will cut 17 percent of its staff, or 65 jobs.
September 30, 2016: Shares of Threshold Pharma plunged more than 58 percent in pre-market trading after the company announced it was terminating about one-fourth of its workforce following the failure of its Phase II cancer treatment.
September 30, 2016: Boston-based SQZ Biotech, pronounced “squeeze,” announced that it had closed on a Series B financing round worth $16M. The round was led by NanoDimension and Polaris Partners.